
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Hao G. Nguyen MD, PhD, describes the near-infrared, PSMA-targeting fluorophore IS-002, and discusses the background and findings from a
Nguyen is associate professor in residence, Urologic Oncology, Richard and Leilani Grinold Endowed professorship in Urology Education, University of California San Francisco.